Justin W Jackson

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 3

Top Topics

Epithelial Mesenchymal Transition

Transforming Growth Factor

Systemic Sclerosis

Top Venues

Science signaling

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Justin W Jackson, Frederick C Streich, Ajai Pal, George Coricor, Christopher Boston, Christopher T Brueckner, Kaleigh Canonico, Christopher Chapron, Shaun M Cote, Kevin B Dagbay, Francis T Danehy, Mania Kavosi, Sandeep Kumar, Susan Lin, Christopher Littlefield, Kailyn Looby, Rohan Manohar, Constance J Martin, Marcie Wood, Agatha Zawadzka, Stefan Wawersik, Samantha B Nicholls, Abhishek Datta, Alan Buckler, Thomas Schürpf, Gregory J Carven, Mohammed Qatanani, Adam I Fogel
An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis. Science signaling 17 (844) (2024)
Justin W Jackson, Frederick C Streich, Ajai Pal, George Coricor, Christopher Boston, Christopher T Brueckner, Kaleigh Canonico, Christopher Chapron, Shaun M Cote, Kevin B Dagbay, Francis T Danehy, Mania Kavosi, Sandeep Kumar, Susan Lin, Christopher Littlefield, Kailyn Looby, Rohan Manohar, Constance J Martin, Marcie Wood, Agatha Zawadzka, Stefan Wawersik, Samantha B Nicholls, Abhishek Datta, Alan Buckler, Thomas Schürpf, Gregory J Carven, Mohammed Qatanani, Adam I Fogel
An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis. Science signaling 17 (844) (2024)
Constance J Martin, Abhishek Datta, Christopher Littlefield, Ashish Kalra, Christopher Chapron, Stefan Wawersik, Kevin B Dagbay, Christopher T Brueckner, Anastasia Nikiforov, Francis T Danehy, Frederick C Streich, Christopher Boston, Allison Simpson, Justin W Jackson, Susan Lin, Nicole Danek, Ryan R Faucette, Pichai Raman, Allan D Capili, Alan Buckler, Gregory J Carven, Thomas Schürpf
Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. Science translational medicine 12 (536) (2021)